Actinium-225 PSMA therapy is an emerging treatment for advanced prostate cancer that focuses on delivering targeted radiation ...

Prostate cancer poses significant challenges for many patients. Radioligand therapies have offered hope by targeting cancer cells with precision. While Lutetium-177 therapy has been effective for many ...

The study will look to confirm the tolerability of the combination and determine the optimal dose of Actimab-A when used with Venetoclax and ASTX-727. Dr. Avinash Desai, Actinium’s Chief Medical ...

The study will look to confirm the tolerability of the combination and determine the optimal dose of Actimab-A when used with Venetoclax and ASTX-727. Dr. Avinash Desai, Actinium’s Chief Medical ...

Telix states its automated and high-throughput generator can produce sufficient lead-212 elution for up to 60 clinical doses, ...

Actimab-A is a humanized anti-CD33 antibody conjugated to Actinium-225 (Ac-225). With its potent alpha-particle payload ...

ITM Isotope Technologies Munich SE is gearing up to enter the US market with its radiopharmaceutical therapy, ITM-11 ...

Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a ...

An IAEA expert mission was deployed to Suva, Fiji, to support the recovery and transportation of radium-226 to the USA, where the sources will be used as a feedstock to produce actinium-225, an ...

Prominent examples include the use of lutetium-177 and actinium-225 diagnostic therapies for treating neuroendocrine tumors and prostate cancer. With pharmaceutical companies like Telix ...

MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...